Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
cytomegalovirus immunoglobulin (Kamada Ltd.)
- Development stage
- Discontinued
- Lead developer
- Kamada
- Modality
- Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Cytomegalovirus immunoglobulin (CMV-IGIV), also known as CMV hyperimmunoglobulin, is a purified, sterile solution of immunoglobulin G (IgG) obtained from pooled human plasma of donors with high titers of antibodies against cytomegalovirus (CMV). It is primarily indicated for the prophylaxis of CMV infection and disease in patients undergoing solid organ transplantation (including kidney, liver, lung, heart, and pancreas) and has been used preemptively or adjunctively in hematopoietic stem cell transplant (HSCT) recipients. CMV-IGIV provides passive immunization by neutralizing extracellular CMV particles, preventing viral entry into host cells, and promoting clearance of the virus through antibody-dependent cellular cytotoxicity (ADCC) and complement activation. Key commercial formulations include Cytogam (developed by MassBiologics, CSL Behring, and Kamada) and Cytotect/Megalotect (developed by Biotest).
- Brand names
- CymvigoCytogamCytoglobinCytomegatectCytotectCytotect CPIvegam-cmvMegalotectMegalotect CP
- Other names
- CMV hyperimmunoglobulinCMV hyperimmunoglobulinsCMV-IGCMV-IGIVCMVIGcytomegalovirus immune globulincytomegalovirus immune globulin intravenous (human)human anti-cytomegalovirus immunoglobulinhuman cytomegalovirus immunoglobulin
02
Targets
gB (Human cytomegalovirus glycoprotein B)GH (Growth hormone)
Beyond the preview
Go deeper on cytomegalovirus immunoglobulin (Kamada Ltd.).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on cytomegalovirus immunoglobulin (Kamada Ltd.).